Form DEFA14A Amneal Pharmaceuticals,
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES
EXCHANGE ACT OF 1934
(Amendment No. )
![]() |
Filed by the Registrant | ![]() |
Filed by a Party other than the Registrant |
| Check the appropriate box: | |
![]() |
Preliminary Proxy Statement |
![]() |
Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) |
![]() |
Definitive Proxy Statement |
![]() |
Definitive Additional Materials |
![]() |
Soliciting Material under §240.14a-12 |

Amneal Pharmaceuticals, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check all boxes that apply): | |
![]() |
No fee required. |
![]() |
Fee paid previously with preliminary materials. |
![]() |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |


Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
- Omni Ventures Closes Oversubscribed Fund I to Advance Digitization of Manufacturing Technology
- Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share
